Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 29.0
(0.69%)
SEK 29.0
(0.69%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 12.16 Million SEK | 33.07% |
| 2022 | 9.14 Million SEK | 113.77% |
| 2021 | 4.27 Million SEK | 135.18% |
| 2020 | 1.81 Million SEK | 143.51% |
| 2019 | 747 Thousand SEK | 122.92% |
| 2018 | -3.25 Million SEK | -164.59% |
| 2017 | 5.04 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 161 Thousand SEK | -94.53% |
| 2024 Q3 | 9.58 Million SEK | 5850.93% |
| 2024 Q1 | 2.94 Million SEK | -27.47% |
| 2023 FY | 12.16 Million SEK | 33.07% |
| 2023 Q3 | 531 Thousand SEK | -88.69% |
| 2023 Q2 | 4.69 Million SEK | 62.79% |
| 2023 Q1 | 2.88 Million SEK | 123.22% |
| 2023 Q4 | 4.05 Million SEK | 664.41% |
| 2022 Q2 | 3.8 Million SEK | 32.04% |
| 2022 Q1 | 2.88 Million SEK | 213.15% |
| 2022 Q3 | 1.16 Million SEK | -69.3% |
| 2022 FY | 9.14 Million SEK | 113.77% |
| 2022 Q4 | 1.29 Million SEK | 10.62% |
| 2021 Q4 | 920 Thousand SEK | -39.23% |
| 2021 Q3 | 1.51 Million SEK | 100.26% |
| 2021 Q2 | 756 Thousand SEK | -24.7% |
| 2021 Q1 | 1 Million SEK | 245.09% |
| 2021 FY | 4.27 Million SEK | 135.18% |
| 2020 Q4 | -692 Thousand SEK | -81.15% |
| 2020 Q2 | 2.48 Million SEK | 505.61% |
| 2020 FY | 1.81 Million SEK | 143.51% |
| 2020 Q1 | 410 Thousand SEK | -96.58% |
| 2020 Q3 | -382 Thousand SEK | -115.38% |
| 2019 Q3 | -6.88 Million SEK | -42.1% |
| 2019 Q4 | 11.97 Million SEK | 273.77% |
| 2019 FY | 747 Thousand SEK | 122.92% |
| 2019 Q2 | -4.84 Million SEK | -855.14% |
| 2019 Q1 | 642 Thousand SEK | 0.0% |
| 2018 FY | -3.25 Million SEK | -164.59% |
| 2017 FY | 5.04 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | 194.863% |
| BioArctic AB (publ) | 229.24 Million SEK | 94.692% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 167.995% |
| CombiGene AB (publ) | -35.66 Million SEK | 134.12% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 108.014% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 174.21% |
| OncoZenge AB (publ) | -15.9 Million SEK | 176.525% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 104.895% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 102.61% |
| Mendus AB (publ) | -101.61 Million SEK | 111.975% |
| LIDDS AB (publ) | -40.2 Million SEK | 130.267% |
| Lipum AB (publ) | -37.17 Million SEK | 132.732% |
| Simris Alg AB (publ) | -37.3 Million SEK | 132.62% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 128.821% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 151.266% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 103.135% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 106.773% |
| Ziccum AB (publ) | -21.41 Million SEK | 156.833% |
| AcouSort AB (publ) | -17.08 Million SEK | 171.21% |
| Active Biotech AB (publ) | -45.8 Million SEK | 126.57% |
| Alzinova AB (publ) | -16.48 Million SEK | 173.841% |
| Amniotics AB (publ) | -30.87 Million SEK | 139.42% |
| Camurus AB (publ) | 431.44 Million SEK | 97.179% |
| Cantargia AB (publ) | -280.02 Million SEK | 104.346% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 157.698% |
| Genovis AB (publ.) | 61.5 Million SEK | 80.213% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 110.738% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 132.826% |
| Intervacc AB (publ) | -102.85 Million SEK | 111.832% |
| Kancera AB (publ) | -64.88 Million SEK | 118.754% |
| Karolinska Development AB (publ) | 5.38 Million SEK | -125.938% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 200.338% |
| NextCell Pharma AB | -41.95 Million SEK | 129.002% |
| Saniona AB (publ) | -95.81 Million SEK | 112.701% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 103.914% |
| Xintela AB (publ) | -54.08 Million SEK | 122.501% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 2878.311% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 173.649% |
| Corline Biomedical AB | -1.8 Million SEK | 772.692% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 106.843% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 121.416% |
| Aptahem AB (publ) | -11.11 Million SEK | 209.504% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 109.888% |
| Fluicell AB (publ) | -26.55 Million SEK | 145.827% |
| Biovica International AB (publ) | -124.82 Million SEK | 109.749% |
| Abliva AB (publ) | -95.5 Million SEK | 112.741% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 103.723% |
| 2cureX AB (publ) | -32.51 Million SEK | 137.422% |
| I-Tech AB | 20.2 Million SEK | 39.766% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 101.463% |
| Cyxone AB (publ) | -22.98 Million SEK | 152.934% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 113.314% |
| Biosergen AB | -27.03 Million SEK | 145.009% |
| Nanologica AB (publ) | -75.15 Million SEK | 116.191% |
| SynAct Pharma AB | -215.81 Million SEK | 105.639% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 127.623% |
| BioInvent International AB (publ) | -330.3 Million SEK | 103.684% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 104.885% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 222.548% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 111.135% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 204.204% |